Luz Tonantzin Orozco Moreno

Dr. Luz Tonantzin Orozco Moreno


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Alma D. Campos-ParraAlma D. Campos-Parra
Alma D. Campos-Parra
Eduardo López-UrrutiaEduardo López-Urrutia
Eduardo López-Urrutia
LMLuz Tonantzin Orozco Moreno
Luz Tonantzin Orozco Moreno
César López-CamarilloCésar López-Camarillo
César López-Camarillo
TMThuluz Meza-Menchaca
Thuluz Meza-Menchaca
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
Predicting response to systemic treatments in breast cancer (BC) patients is an urgent, yet still unattained health aim. Easily detectable molecules such as long non-coding RNAs (lncRNAs) are the ideal biomarkers when they act as master regulators of many resistance mechanisms, or of mechanisms that are common to more than one treatment. These kinds of markers are pivotal in quasi-personalized treatment selection, and consequently, in improvement of outcome prediction. In order to provide a better approach to understanding development of disease and resistance to treatments, we reviewed current literature searching for lncRNA-associated systemic BC treatments including endocrine therapies, aromatase inhibitors, selective estrogen receptor modulators (SERMs), trastuzumab, paclitaxel, docetaxel, 5-fluorouracil (5-FU), anthracyclines, and cisplatin. We found that the engagement of lncRNAs in resistance is well described, and that lncRNAs such as urotelial carcinoma-associated 1 (UCA1) and regulator of reprogramming (ROR) are indeed involved in multiple resistance mechanisms, which offers tantalizing perspectives for wide usage of lncRNAs as treatment resistance biomarkers. Thus, we propose this work as the foundation for a wide landscape of functions and mechanisms that link more lncRNAs to resistance to current and new treatments in years of research to come.